Literature DB >> 31640894

Response to the combination of dabrafenib, trametinib and osimertinib in a patient with EGFR-mutant NSCLC harboring an acquired BRAFV600E mutation.

Fei Zhou1, Wencheng Zhao1, Xiaoxia Chen1, Jie Zhang2, Caicun Zhou1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31640894     DOI： 10.1016/j.lungcan.2019.10.014

Source DB:  PubMed          Journal:  Lung Cancer        ISSN： 0169-5002            Impact factor:   5.705


× No keyword cloud information.
  4 in total

1.  Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient.

Authors:  Maurício Fernando Silva Almeida Ribeiro; Franciele Hinterholz Knebel; Fabiana Bettoni; Rodrigo Saddi; Karina Perez Sacardo; Felipe Sales Nogueira Amorim Canedo; João Victor Machado Alessi; Andrea Kazumi Shimada; José Flávio Gomes Marin; Anamaria Aranha Camargo; Artur Katz
Journal:  NPJ Precis Oncol       Date:  2021-02-12

2.  Combined targeting of EGFR and BRAF triggers regression of osimertinib resistance by using osimertinib and vemurafenib concurrently in a patient with heterogeneity between different lesions.

Authors:  Mengyao Sun; Xu Wang; Yinghui Xu; Chao Sun; Ye Guo; Shi Qiu; Renshan Zhao; Wenhao Zhu; Kewei Ma
Journal:  Thorac Cancer       Date:  2021-12-27       Impact factor: 3.500

3.  EGFR/BRAF/MEK co-inhibition for EGFR-mutated lung adenocarcinoma patients with an acquired BRAFV600E mutation: a case report and review of literature.

Authors:  Ran Zeng; Lifeng Luo; Xianwen Sun; Zhiyao Bao; Wei Du; Ranran Dai; Wei Tang; Beili Gao; Yi Xiang
Journal:  Cancer Drug Resist       Date:  2021-12-01

Review 4.  The Evolution of BRAF Activation in Non-Small-Cell Lung Cancer.

Authors:  Longyao Zhang; Linpeng Zheng; Qiao Yang; Jianguo Sun
Journal:  Front Oncol       Date:  2022-07-13       Impact factor: 5.738
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.